LKKTETQ raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
== Structure == Three distinct fiber types have been identified within the dermis: oxytalan, elaunin, and elastic fibers. The most superficial of these, the oxytalan fibers, are extremely slender and oriented perpendicularly to the dermoepidermal junction. They arise from a plexus exhibiting the staining properties of elaunin fibers, which in turn are contiguous with the thicker elastic fibers of the reticular dermis. Electron microscopy shows that oxytalan fibers consist of bundles of tubular microfibrils measuring approximately 10–12 nm in diameter. In deeper dermal layers, these bundles contain a central amorphous substance. Elaunin fibers contain only small amounts of this amorphous material, whereas in elastic fibers it is abundant and densely compacted. The structure of Elaunin fibers allows for repeated stretching or pressure because they are made up of microfibrils and small amounts of elastic fibers (Sawada et al, 2006.) These elaunin fibers have moderate tissue elasticity and plays an important role by allowing tissues such as skin and mucosa to stretch during everyday movements without becoming permanently damaged. Additionally, the fibers support blood vessels by maintaining the shape of vessel lumen, especially during sudden or repeated changes in pressure. The flexibility of elaunin fibers allows for a certain level of stretch that is still strong enough to support moving tissues but does not recoil like fully developed elastic fibers do.
=== March === 1 March – 2024 Rochdale by-election: Sir Keir Starmer apologises to the voters of Rochdale for disowning the Labour Party's candidate, but says it was "the right decision". In a statement outside 10 Downing Street, Sunak warns that Islamists and far-right extremists, which he describes as "two sides of the same extremist coin", are trying to "deliberately" undermine the UK's "multi-faith democracy", and says the UK must face them down. Figures from the National Audit Office show the UK government will pay Rwanda a total of £350m for the agreement to take asylum seekers, with £150,000 also being paid to Rwanda for each person sent there. Conservative peer Lord Bamford, chairman of JCB, retires from the House of Lords. 2–3 March – The London Labour conference is held at the Leonardo Royal Hotel in Tower Bridge. 4 March – Sunak says the UK economy is "getting on the right track" ahead of what is expected to be the last budget before the next election. George Galloway is sworn in as an MP at Westminster. Paul Scully, MP for Sutton and Cheam, announces he is standing down from Parliament at the next general election. Lee Waters announces he is stepping down as Wales's Transport Minister when the new First Minister of Wales is elected. 5 March – A bid by the Welsh Conservatives and Welsh Liberal Democrats to change planned reforms to the way Senedd members are elected from the 2026 election is rejected by the parliament. 6 March – Chancellor Jeremy Hunt delivers the 2024 United Kingdom budget.
The heavy isotope plutonium-244 has a half-life long enough that extreme trace quantities should have survived primordially (from the Earth's formation) to the present, but so far experiments have not yet been sensitive enough to detect it. Both plutonium-239 and plutonium-241 are fissile, meaning they can sustain a nuclear chain reaction, leading to applications in nuclear weapons and nuclear reactors. Plutonium-240 has a high rate of spontaneous fission, raising the neutron flux of any sample containing it. The presence of plutonium-240 limits a plutonium sample's usability for weapons or its quality as reactor fuel, and the percentage of plutonium-240 determines its grade (weapons-grade, fuel-grade, or reactor-grade). Plutonium-238 has a half-life of 87.7 years and emits alpha particles. It is a heat source in radioisotope thermoelectric generators, which are used to power some spacecraft. Plutonium isotopes are expensive and inconvenient to separate, so particular isotopes are usually manufactured in specialized reactors. Producing plutonium in useful quantities for the first time was a major part of the Manhattan Project during World War II that developed the first atomic bombs. The Fat Man bombs used in the Trinity nuclear test in July 1945, and in the bombing of Nagasaki in August 1945, had plutonium cores. Human radiation experiments studying plutonium were conducted without informed consent, and several criticality accidents, some lethal, occurred after the war.
Sources: en.wikipedia.org
==== Other territories ==== Australia. Ashmore and Cartier Islands - Special authorisation required. Belarus. Brest and Grodno - Visa not required for 10 days. China. Hainan - Visa not required for 30 days. China. Tibet Autonomous Region - Tibet Travel Permit required (10 USD). Colombia. San Andrés and Leticia - Visitors arriving at Gustavo Rojas Pinilla International Airport and Alfredo Vásquez Cobo International Airport must buy tourist cards on arrival. Ecuador. Galápagos - 60 days; Visitors must pre-register to receive a 20 USD Transit Control Card (TCT). Eritrea outside Asmara – To travel in the rest of the country, a Travel Permit for Foreigners is required (20 Eritrean nakfa). Fiji. Lau Province - Special permission required. Greece Mount Athos - Special permit required (4 days: 25 euro for Orthodox visitors, 35 euro for non-Orthodox visitors, 18 euro for students). There is a visitors' quota: maximum 100 Orthodox and 10 non-Orthodox per day and women are not allowed. India. Protected Area Permit (PAP) required for whole states of Nagaland and Sikkim and parts of states Manipur, Arunachal Pradesh, Uttaranchal, Jammu and Kashmir, Rajasthan, Himachal Pradesh. Restricted Area Permit (RAP) required for all of Andaman and Nicobar Islands and parts of Sikkim. Some of these requirements are occasionally lifted for a year. Iran. Kish Island - Visa not required. Kazakhstan. Closed cities - Special permission required for the town of Baikonur and surrounding areas in Kyzylorda Oblast, and the town of Gvardeyskiy near Almaty.
==== MeSH D12.125.166 – amino acids, sulfur ==== MeSH D12.125.166.175 – cystathionine MeSH D12.125.166.215 – cysteic acid MeSH D12.125.166.230 – cysteine MeSH D12.125.166.230.259 – acetylcysteine MeSH D12.125.166.230.310 – carbocysteine MeSH D12.125.166.230.330 – cysteinyldopa MeSH D12.125.166.230.369 – cystine MeSH D12.125.166.230.700 – selenocysteine MeSH D12.125.166.388 – ethionine MeSH D12.125.166.498 – homocysteine MeSH D12.125.166.498.050 – s-adenosylhomocysteine MeSH D12.125.166.554 – homocystine MeSH D12.125.166.676 – methionine MeSH D12.125.166.676.180 – s-adenosylmethionine MeSH D12.125.166.676.450 – n-formylmethionine MeSH D12.125.166.676.450.440 – n-formylmethionine leucyl-phenylalanine MeSH D12.125.166.676.620 – methionine sulfoximine MeSH D12.125.166.676.620.125 – buthionine sulfoximine MeSH D12.125.166.676.900 – selenomethionine MeSH D12.125.166.676.950 – vitamin u MeSH D12.125.166.786 – penicillamine MeSH D12.125.166.786.500 – s-nitroso-n-acetylpenicillamine MeSH D12.125.166.800 – thiopronine MeSH D12.125.166.893 – thiorphan
See polycythemia vera for management of primary polycythemia, which involves reducing thrombotic risk, symptom amelioration and monitoring for further hematologic complications. Treatment can include phlebotomy, aspirin, and myelosuppressive or cytoreductive medications based on risk stratification. For secondary polycythemia, management involves addressing the underlying etiology of increased erythropoeitin production, such as smoking cessation, CPAP for sleep apnea, or removing any EPO-producing tumours. Phlebotomy is not typically recommended for patients with physiologic polycythemia, who rely on additional red cell mass for necessary oxygen delivery, unless the patient is clearly symptomatic and experiences relief from phlebotomy. It is unclear if patients with secondary polycythemia are at elevated thrombotic risk, but aspirin can be considered for patients at elevated cardiovascular risk or for patients with Chuvash polycythemia. The first-line treatment for post-transplant erythrocytosis specificity is angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.